Other · developed by ELI LILLY &
LY3016859 is an agent administered intravenously and studied in knee osteoarthritis, diabetic neuropathic pain and chronic low-back pain.
Summary written with AI from the sources listed at the end of this page.
Chronic Low-back PainDiabetic Neuropathic PainOsteoarthritis, Knee
Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →